Additional file 1 of Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Additional file 1: Figure S1. Historical clinical (A) and histopathological (B) arthritic scores depicting the dose-dependent effect of Infliximab on Tg197 arthritic pathology. All data are shown as mean± SEM. Figure S2. Clinical (A) and histopathological (B) arthritic scores showing the response of Tg197 animals treated with bosutinib (75 mg/Kg) administered either alone or in combination with 1mg/Kg Infliximab in comparison to two doses of Infliximab (10mg/Kg). All data are shown as mean± SEM (***p-value≤0.0001). Figure S3. Historical clinical (A) and histopathological (B) arthritic scores showing the response of Tg197 animals to treatment with different commercially available anti-hTNF treatments (Infliximab 10mg/Kg, Adalimumab 10mg/Kg, Golimumab 3mg/Kg, and Etanercept 10mg/Kg). Infliximab, Adalimumab and Golimumab were administered intraperitoneally twice weekly. Etanercept was administered subcutaneously thrice weekly. All data are shown as mean± SEM. Figure S4. Set overlaps for 3733 genes whose expression was significantly altered (|logFC|>=1, adjusted p value<=0.05) compared to WT controls in at least one of the three treatments. Linked dots correspond to genes shared between categories, shown in the horizontal bars. Vertical bars correspond to the number of genes belonging to each set.